Cortexyme (CRTX) Competitors

Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment.

Is CRTX or OMCL more profitable?

Cortexyme has a net margin of 0.00% compared to Omnicell's net margin of -1.66%. Omnicell's return on equity of 2.55% beat Cortexyme's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cortexyme	N/A	-70.96%	-63.53%
Omnicell	-1.66%	2.55%	1.35%

Does the media favor CRTX or OMCL?

In the previous week, Omnicell had 3 more articles in the media than Cortexyme. MarketBeat recorded 4 mentions for Omnicell and 1 mentions for Cortexyme. Cortexyme's average media sentiment score of 1.11 beat Omnicell's score of 0.18 indicating that Cortexyme is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cortexyme	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings and valuation, CRTX or OMCL?

Omnicell has higher revenue and earnings than Cortexyme. Omnicell is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cortexyme	N/A	N/A	-$89.94M	-$2.97	-0.56
Omnicell	$1.15B	1.72	-$20.37M	-$0.39	-109.15

Do institutionals & insiders have more ownership in CRTX or OMCL?

63.2% of Cortexyme shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 27.9% of Cortexyme shares are held by company insiders. Comparatively, 2.6% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts prefer CRTX or OMCL?

Omnicell has a consensus target price of $50.00, indicating a potential upside of 17.45%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Cortexyme.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cortexyme	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Omnicell	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Which has more risk & volatility, CRTX or OMCL?

Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Does the MarketBeat Community favor CRTX or OMCL?

Omnicell received 345 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 66.89% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote.

Company	Underperform	Outperform
Cortexyme	Outperform Votes 154 64.44%	Underperform Votes 85 35.56%
Omnicell	Outperform Votes 499 66.89%	Underperform Votes 247 33.11%

Summary

Omnicell beats Cortexyme on 12 of the 17 factors compared between the two stocks.